• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

CeloNova BioSciences

Biomet vet Serbousek to succeed Mason as Orthofix CEO | Personnel Moves, August 13, 2019

August 13, 2019 By Brad Perriello

Orthofix (NSDQ:OFIX) last week named a successor for president & CEO Brad Mason in November, tapping Jon Serbousek as president of its spine business effective August 5. Mason is slated to retire Oct. 31; Serbousek, a 30-year medtech veteran with stints at Biomet, Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ) unit DePuy Orthopaedics, is due to […]

Filed Under: Business/Financial News, Featured Tagged With: Accuray Inc., Bill & Melinda Gates Foundation, CeloNova BioSciences, Corinth MedTech, MiMedx Group Inc., Nimbus Concepts, On Target Labs, Orthofix, Personnel Moves, Ra Medical, ReShape Lifesciences, Second Sight, Stryker, Virginia Bio

FDA clears expansion of CeloNova’s nano-coated coronary stent trial

October 26, 2017 By Sarah Faulkner

CeloNova Biosciences said today that the FDA approved an expansion of the on-going clinical trial for its Cobra PzF nano-coated coronary stent with 14-day dual antiplatelet therapy in complex patients, like people who are at a high risk of bleeding. The company touted its Cobra Reduce trial as the first randomized control trial to study 14-day […]

Filed Under: Clinical Trials, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceutical, Stents, Vascular Tagged With: CeloNova BioSciences

VC shops back CeloNova BioSciences

August 7, 2017 By Sarah Faulkner

CeloNova BioSciences said today that it inked a 4-year financing deal with Congruent Investment Partners and SWK Holdings Corp. The funds are slated to support CeloNova’s ongoing clinical trials and product initiatives, including the launch of its Cobra PzF NanoCoated coronary stent. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Cardiovascular, Clinical Trials, Funding Roundup, Vascular Tagged With: CeloNova BioSciences

FDA clears CeloNova’s Cobra PzF coronary stent

March 1, 2017 By Fink Densford

CeloNova BioSciences said today it won FDA approval for its Cobra PzF nanocoated coronary stent system. The device is now cleared with indications for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to de novo lesions in native coronary arteries with a reference vessel diameter of 2.5-4mm and lesion length of less […]

Filed Under: Cardiovascular, Food & Drug Administration (FDA), Regulatory/Compliance, Stents Tagged With: CeloNova BioSciences

CeloNova touts study on Cobra PzF “nanocoated” coronary stents

January 25, 2017 By Fink Densford

CeloNova BioSciences yesterday released data from the Shield trial of its Cobra PzF nanocoated coronary stent, announcing the trial met its primary and secondary endpoints. Results from the study were published in the Journal of the American College of Cardiology: Cardiovascular Interventions this month. The Cobra PzF coronary stent has a novel Polyzene-F nano-coating and thin-strut […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Stents Tagged With: CeloNova BioSciences

Analogic CEO Green steps away | Personnel Moves Nov 4, 2016

November 4, 2016 By Fink Densford

Analogic (NSDQ:ALOG) said late last month its prez and CEO James Green has stepped away from his position to pursue other opportunities. Company director and former Enovate Medical exec chair and CEO Dr. Fred Parks has been named to take over Green’s position. “Jim Green led Analogic during a period of meaningful development and growth, and […]

Filed Under: Business/Financial News Tagged With: 3DIcon, Alphabet (Google), Analogic, Carl Zeiss Meditec, CeloNova BioSciences, DeepMind, Endo Health, Haemonetics, InVivo Therapeutics, nanovibronix, Personnel Moves, Strata Skin Sciences

Seno Medical grabs ex-CeloNova CFO Davis | Personnel Moves August 12, 2016

August 12, 2016 By Fink Densford

Seno Medical grabs ex-CeloNova CFO Davis Seno Medical Instuments said this week it tapped former CeloNova BioSciences chief financial officer Eric Davis to take over the CFO role at Seno Medical. Prior to his years at CeloNova, Davis operated as CFO and operating officer at Genesis Networks Enterprises. Seno Medical said that Davis has more than […]

Pages: Page 1 Page 2 Page 3 Page 4

Filed Under: Business/Financial News Tagged With: Allergan, CeloNova BioSciences, Cerus Corp., CooperVision, Endologix, InVivo Therapeutics, Medtronic, Personnel Moves, ReVision Optics Inc., Seno Medical Instruments, TriVascular, UnitedHealth Group

Boston Scientific to put up $70m for CeloNova’s interventional radiology line

November 10, 2015 By Brad Perriello

Boston Scientific (NYSE:BSX) said today that it agreed to pay $70 million up front for CeloNova BioSciences‘ interventional radiology business, including its drug-eluting microsphere technology for chemotherapy and spherical embolic products for treating uterine fibroids and other conditions. The deal also includes an unspecified amount tied to regulatory and sales milestones, Marlborough, Mass.-based Boston Scientific said. “As we continue […]

Filed Under: Mergers & Acquisitions, Radiosurgery/Radiation therapy Tagged With: Boston Scientific, CeloNova BioSciences

CeloNova wins FDA nod for U.S. stent trial

September 21, 2015 By Fink Densford

Interventional cardiology and radiology company CeloNova BioSciences said today it won FDA approval to launch an investigational device exemption trial of its Cobra PzF coronary stent system for treating patients with a high risk of bleeding. The prospective, randomized Cobra-Reduce trial is being led by Dr. Adnan Kastrati and examine the use of the stent during percutaneous […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Food & Drug Administration (FDA), Stents Tagged With: CeloNova BioSciences

CeloNova launches coronary stent trial

September 14, 2015 By Fink Densford

Interventional cardiology and radiology company CeloNova BioSciences said today it launched a trial of its novel Cobra PzF coronary stent for treating heart disease. The e-Cobra study, a prospective registry in France, is slated to enroll 1,000 patients with a primary endpoint assessing the rate of major adverse cardiac events, such as cardiac death, myocardial […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Stents Tagged With: CeloNova BioSciences

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS